Introduction
============

Hypertension, one of the most common diseases worldwide, is estimated to affect one quarter of all adults, and has been identified as the leading cause of mortality and the third cause of disability-adjusted life years worldwide.[@b1-ndt-11-1121] According to a report by Kearney et al the total number of adults with hypertension in 2025 was predicted to increase to 1.56 billion worldwide.[@b2-ndt-11-1121] Identifying and characterizing modifiable risk factors of hypertension remain important for public health and clinical medicine.

Hypertension has a multifactorial etiology, where genetic as well as psychosocial and environmental factors appear to be of importance.[@b3-ndt-11-1121],[@b4-ndt-11-1121] However, there are complex physiological processes involved and the linkage among psychosocial factors and hypertension is not fully understood.[@b5-ndt-11-1121]--[@b7-ndt-11-1121] Anxiety is one of the most common psychiatric illnesses in adults and is a major public health problem in many countries,[@b8-ndt-11-1121],[@b9-ndt-11-1121] damaging the affected individual's health and quality of life.[@b10-ndt-11-1121] Because both hypertension and anxiety confer significant public health challenges, the association between the two conditions has recently attracted attention.

A number of epidemiological studies have been conducted to investigate this association, with inconsistent results reported. Some investigations show that anxiety is associated with hypertension, individuals with anxiety having a higher risk of hypertension than those without anxiety.[@b11-ndt-11-1121]--[@b14-ndt-11-1121] Further, hypertension patients have a higher risk of anxiety than those without hypertension.[@b15-ndt-11-1121],[@b16-ndt-11-1121] However, some researchers do not support the role of anxiety symptoms in the development of hypertension.[@b17-ndt-11-1121],[@b18-ndt-11-1121] Some studies have even reported that anxiety is associated with a decrease in blood pressure.[@b19-ndt-11-1121],[@b20-ndt-11-1121] To date, there has not been a meta-analysis to explore the association between anxiety and hypertension. Therefore, we summarized the available data from cross-sectional and prospective studies, and performed meta-analyses to investigate the cross-sectional correlation and longitudinal relationship between anxiety and hypertension.

Methods
=======

Search strategy
---------------

A comprehensive search, restricted to human studies published in the English or Chinese language, was performed using the following databases: PubMed, ISI Web of Science, EMBASE, PsycInfo, China National Knowledge Infrastructure, China Biology Medical literature database, and Database of Chinese Scientific and Technical Periodicals. The search terms ("anxiety" or "worry" or "post-traumatic stress" or "panic" or "agoraphobia" or "phobia" or "obsessive-compulsive") and ("hyperten\*" or "high blood pressure") were used in various combinations for relevant articles without time restriction ([Figure 1](#f1-ndt-11-1121){ref-type="fig"} shows details of the search process and study selection). The last search was performed on November 6, 2014. In addition, we searched and identified studies not captured by our database by reviewing the reference lists in retrieved articles.

Inclusion criteria
------------------

Articles were considered for inclusion in the systematic review if: the authors reported data from an original, peer-reviewed study (ie, not case reports, comments, letters, meeting abstracts, or review articles); the study was a cross-sectional or prospective study with an adult population (age ≥18 years); the exposure of interest was one or more types of anxiety defined according to standard instruments: and odds ratio (OR), relative risk, or hazard ratio (HR) with 95% confidence interval (CI; or data to calculate it) were reported. If multiple articles were published from the same population, the most informative report was included.

Data extraction and quality assessment
--------------------------------------

The following data were extracted from each study: the first author's name, year of publication, study site, number of participants, and years of follow-up for prospective studies, participants' characteristics (age range or mean age and sex composition), anxiety measures, analysis strategy (statistical models and covariates adjusted in the models), and results (prevalence, incidence, unadjusted or adjusted OR, and 95% CI). For some studies providing ORs for different types of anxiety, we used meta-analysis to incorporate these values into one combined OR that presents the association of anxiety with hypertension. The nine-star Newcastle-Ottawa Scale[@b21-ndt-11-1121] and eleven-score Agency for Healthcare Research and Quality[@b22-ndt-11-1121] were used, respectively, to estimate the quality of prospective studies and cross-sectional studies. Study inclusion, data extraction, and quality assessment were performed by two independent investigators (YP and JY). Any disagreement was settled by discussion among all of the authors.

Statistical analysis
--------------------

The research strategy has been described in previous studies.[@b23-ndt-11-1121] The pooled measure was calculated as the inverse variance-weighted mean of the logarithm of the OR (HR) with 95% CI to assess the strength of association between anxiety disorders and risk of hypertension. Heterogeneity among studies was assessed using the *Q* test and the *I*^2^ statistic, which describes the proportion of total variation attributable to between-study heterogeneity as opposed to random error or chance.[@b24-ndt-11-1121] In the presence of substantial heterogeneity (*I*^2^\>50%),[@b25-ndt-11-1121] the DerSimonian and Laird random effect model (REM) was applied as the pooling method; otherwise, the fixed effect model was adopted. Meta-regression with restricted maximum likelihood estimation was performed to assess the potentially important covariates exerting substantial impact on between-study heterogeneity. The "leave one out" sensitivity analysis[@b26-ndt-11-1121] was conducted using *I*^2^\>50% as the criterion to assess the key studies with substantial impact on between-study heterogeneity. An analysis of influence was conducted,[@b27-ndt-11-1121] which describes how robust the pooled estimator is to removal of individual studies. An individual study is suspected of excessive influence if the point estimate of its omitted analysis lies outside the 95% CIs of the combined analysis. Publication bias was estimated using Egger's regression asymmetry test.[@b28-ndt-11-1121] All statistical analyses were performed using STATA/SE version 13.1 (Stata Corporation, College Station, TX, USA). All *P*-values were two-sided, and those less than 0.05 were considered to be statistically significant.

Results
=======

Literature search and study selection
-------------------------------------

The study's identified and selected procedures are summarized in [Figure 1](#f1-ndt-11-1121){ref-type="fig"}. Twenty-one studies were finally included in our analysis. Among them, 13 cross-sectional studies[@b11-ndt-11-1121],[@b15-ndt-11-1121],[@b18-ndt-11-1121],[@b20-ndt-11-1121],[@b29-ndt-11-1121]--[@b37-ndt-11-1121] (two in the USA, five in Europe, three in the People's Republic of China, one in Brazil, one in South Africa, and one worldwide) and eight prospective studies[@b6-ndt-11-1121],[@b12-ndt-11-1121]--[@b14-ndt-11-1121],[@b17-ndt-11-1121],[@b38-ndt-11-1121]--[@b40-ndt-11-1121] (six in the USA and two in Europe) of the association between anxiety and hypertension were included in the analysis. General characteristics in the published articles included in this meta-analysis are shown in [Tables 1](#t1-ndt-11-1121){ref-type="table"} and [2](#t2-ndt-11-1121){ref-type="table"}. The duration of follow-up ranged from 1 to 25 years for the prospective studies. Stars in [Tables 1](#t1-ndt-11-1121){ref-type="table"} and [2](#t2-ndt-11-1121){ref-type="table"} indicate the quality of the study. Among the 13 studies in [Table 1](#t1-ndt-11-1121){ref-type="table"}, three scored nine stars, five scored eight stars, and five scored seven stars. Among the eight studies in [Table 2](#t2-ndt-11-1121){ref-type="table"}, one scored nine stars, five scored eight stars, and one scored six stars. The ORs were extracted or calculated from the original articles. Other characteristics, such as age of participants, sample size, and diagnostic criteria for anxiety were also presented in [Tables 1](#t1-ndt-11-1121){ref-type="table"} and [2](#t2-ndt-11-1121){ref-type="table"}.

Cross-sectional studies of the association between anxiety and hypertension
---------------------------------------------------------------------------

Thirteen cross-sectional studies including 151,389 subjects were included in the analysis of the association of anxiety with risk of hypertension. REM was used because substantially significant between-study heterogeneity was observed (*P*~Q~\<0.001; *I*^2^=84.9%). Pooled results showed that anxiety had a significant positive association with hypertension (OR 1.40, 95% CI 1.20--1.62; [Figure 2](#f2-ndt-11-1121){ref-type="fig"}). Significant publication bias was detected (*P*=0.016). After trim and fill analysis, the final result was still significant (OR 1.18, 95% CI 1.02--1.37).

Prospective studies of anxiety predicting hypertension risk
-----------------------------------------------------------

Eight prospective studies investigated the association between the baseline anxiety status and incident hypertension with a total sample size of 80,146 and 2,394 hypertension case subjects. Characteristics of the studies are shown in [Table 2](#t2-ndt-11-1121){ref-type="table"}. The pooled adjusted HR by REM was 1.55 (95% CI 1.24--1.94; [Figure 3](#f3-ndt-11-1121){ref-type="fig"}), with strong heterogeneity detected (*P*~Q~\<0.001; *I*^2^=84.6%). No publication bias was detected (*P*=0.663).

Sources of heterogeneity and sensitivity analysis
-------------------------------------------------

The strong heterogeneities between studies were found in both cross-sectional studies and prospective studies. The univariate meta-regression, with the covariates of location (categorized as American, European, East Asian, and other), diagnostic criteria for anxiety (categorized as structured diagnostic interviews, ie, Diagnostic and Statistical Manual of Mental Disorders or International Classification of Diseases, and self-report symptom scales), age (categorized only as middle-aged and other) and sex, sample size, year of publication, quality, and years of follow-up (≥7 and \<7, only for prospective study), showed that none of the aforementioned covariates had a significant impact on between-study heterogeneity.

Subgroup analyses for location, diagnostic criteria for anxiety, age, sex, years of follow-up (only for prospective study) also did not find a source of heterogeneity and indicated that the effects of anxiety in nearly all subgroups were still significant ([Table 3](#t3-ndt-11-1121){ref-type="table"}).

"Leave one out" sensitivity analysis was performed for the all groups with an *I*^2^\>50%, and the pooled results did not change substantially.

Discussion
==========

To the best of our knowledge, this is the first meta-analysis examining the association between anxiety and hypertension using data from both cross-sectional and prospective studies. We found that anxiety and hypertension were significantly correlated in cross-sectional studies, and a direct association was also observed in prospective studies.

Some cross-sectional studies reported a higher anxiety score in participants with hypertension than for those without hypertension. However, the methods used for assessment of anxiety varied significantly in the different studies. Therefore, we could not pool the anxiety scores; instead, we pooled the ORs, a measure of association that was more consistent across studies. Our final pooled OR was 1.18 (95% CI 1.02--1.37), suggesting that anxiety and hypertension are significantly related. The pooled ORs remained significant in subgroups for location, diagnosis criteria for anxiety, age, and sex. Although strong heterogeneity was found, meta-regression showed that the location, diagnostic criteria for anxiety, age and sex, sample size, year of publication and quality were not the source of between-study heterogeneity.

Cross-sectional studies do not provide the temporal relationship between anxiety and hypertension, so we conducted a further meta-analysis to investigate the association between anxiety and hypertension in prospective studies. The pooled adjusted HR by REM was 1.55 (95% CI 1.24--1.94), indicating that anxiety was an independent risk factor for incident hypertension. This prospective association between anxiety and hypertension was consistent with results from the cross-sectional studies and also in agreement with two recent meta-analyses showing a reciprocal association between anxiety and coronary heart disease[@b41-ndt-11-1121] and between anxiety and heart rate variability.[@b42-ndt-11-1121] Anxiety and depression are closely linked.[@b43-ndt-11-1121] A previous review also shows an increased risk of hypertension in depressed patients and an increased risk of depression in hypertensive patients.[@b44-ndt-11-1121] However, a recent meta-analysis in the elderly does not support that view that hypertension is a possible risk factor of depression.[@b45-ndt-11-1121] Considering current contradictory results in original articles,[@b46-ndt-11-1121] a systematic review should be undertaken to explore the relationship between depression and hypertension with the most up-to-date evidence.

The mechanism between anxiety and hypertension is complex. Generally, anxiety increases blood pressure, systemic vascular resistance, sympathetic activity, plasma renin activity, the homeostasis model, and blood lipids. First, anxiety increases blood pressure in the short term, and the white coat effect derived from anxiety is a typical example.[@b47-ndt-11-1121],[@b48-ndt-11-1121] A recent ambulatory blood pressure monitoring study reported that anxiety disorder was associated with nocturnal and early morning hypertension in hypertensive outpatients.[@b49-ndt-11-1121] Second, anxiety has a close relationship with the renin angiotensin system and increases the level of angiotensin II.[@b50-ndt-11-1121],[@b51-ndt-11-1121] Long-term anxiety may decrease vascular variability, so that persistent vascular resistance leads to hypertension.[@b52-ndt-11-1121] Third, some experiments show that patients with anxiety usually have physiological signs of sympathetic activation, and anxiety can strongly stimulate sympathetic nervous outflow and the vasovagal reflex.[@b53-ndt-11-1121],[@b54-ndt-11-1121] Rozanski et al contend that anxiety can activate the sympathetic nervous system, increase cardiac output, constrict blood vessels, and raise arterial blood pressure.[@b55-ndt-11-1121]

Moreover, a long-term anxiety state will improve the sympathetic response and more easily activate the sympathetic nervous system.[@b56-ndt-11-1121] Activation of the sympathetic nervous system not only reduces renal blood flow, increases renal water and sodium retention, and elevates blood pressure,[@b57-ndt-11-1121] but also damages endothelial cells, causes endothelial dysfunction and increasing the risk of atherosclerosis. Sympathetic activation can cause abnormal hemodynamic changes and abnormal lipid metabolism, such as decreasing high-density lipoprotein cholesterol and increasing low-density lipoprotein cholesterol, which affects endothelial function.[@b58-ndt-11-1121] In addition, endothelial cells in animals with heightened sympathetic nervous activity present structural changes and greater immunoreactivity.[@b59-ndt-11-1121] Fourth, the hypothalamo-pituitary-adrenal axis is the major physiological stress response system in the body.[@b60-ndt-11-1121] When this axis is dysfunctional, increasing steroid hormone secretion causes water and sodium retention, leading to high blood pressure.[@b61-ndt-11-1121] Further, the indirect association between anxiety and increased risk of hypertension might also derive from the characteristics of anxious subjects, who usually have a more unhealthy lifestyle in general. In other words, they usually have some adverse behaviors, such as increased eating, smoking, and alcohol use, and take less exercise, due to stress and anxiety, that impacts health.[@b62-ndt-11-1121]

On the other hand, previous studies have also found that patients with hypertension awareness have an increased risk of anxiety disorders.[@b16-ndt-11-1121],[@b32-ndt-11-1121] Thus, anxiety and hypertension may interact to affect human health. Moreover, anxiety is one of the barriers in treatment of hypertension.[@b63-ndt-11-1121] Khatib et al identify stress, anxiety, and depression as the most common reported barriers hindering or delaying lifestyle modification.[@b64-ndt-11-1121] Therefore, conventional antihypertensive therapy with psychological support and antianxiety treatment, such as diazepam,[@b65-ndt-11-1121] and metacognitive detached mindfulness therapy and stress management training[@b66-ndt-11-1121] could achieve better efficacy in hypertensive patients with anxiety.

This meta-analysis had several strengths. It is the first to explicitly examine the association between anxiety and hypertension on the basis of a comprehensive literature search. This meta-analysis also had a large sample size, which increased the accuracy of the effect estimate. However, the potential limitations of this meta-analysis should be considered. First, it only included English and Chinese language articles; eligible articles published in other languages were not included in this analysis, which may influence the pooled estimated value. Second, because of the inability to obtain raw data, we could perform only a study-level but not a patient-level meta-analysis, which enabled us to adjust for multiple factors. Third, the measurements of anxiety varied among the 21 included studies with regard to different diagnostic instruments, so this might affect the pooled results. We suggest that the DSM-IV should be a preferred instrument to diagnose anxiety disorder in the future because it is the newest standard developed by many experts. Fourth, the outcomes of anxiety and hypertension in our study focused on OR, relative risk, and HR, so some studies with other indices, such as a linear regression coefficient, were excluded. Finally, the heterogeneity between studies included in our study should be paid attention to, although some common factors have been considered to detect the source of heterogeneity.

The results of this meta-analysis indicate an association between anxiety and increased risk of hypertension.

Conclusion
==========

It is important to explore the short-term and long-term effect of anxiety on hypertension. In addition, importance should be attached to the bidirectional association between anxiety and hypertension, especially in the treatment of hypertension. Moreover, the association between anxiety and increased risk of hypertension in this meta-analysis might be confounded by various factors. Therefore, large-scale, randomized controlled trials are recommended to assess the impact of anxiety on incidence rates of hypertension.
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![Random effects meta-analysis of cross-sectional studies of the association between anxiety and hypertension (13 studies included).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** OR, odds ratio; CI, confidence interval.](ndt-11-1121Fig2){#f2-ndt-11-1121}

![Random effects meta-analysis of prospective studies of the association between anxiety and risk of hypertension (eight studies included).\
**Note:** Weights are from random effects analysis.\
**Abbreviations:** HR, hazards ratio; CI, confidence interval.](ndt-11-1121Fig3){#f3-ndt-11-1121}

###### 

Characteristics of cross-sectional studies in the meta-analysis

  Reference                              Study name, country                                  Total sample size   Sample composition             Anxiety measures        Anxiety case/total HP case (prevalence \[%\])   Anxiety case/total non-HP case (prevalence \[%\])   OR (95% CI)         Quality (stars)   Notes
  -------------------------------------- ---------------------------------------------------- ------------------- ------------------------------ ----------------------- ----------------------------------------------- --------------------------------------------------- ------------------- ----------------- --------------------------
  Paterniti et al[@b29-ndt-11-1121]      Etude sur le Vieillissiment Arteriel Study, France   767                 Age 59--71 years; 40.4% M      STAI \>36                                                                                                                   2.71 (1.55--4.76)   9                 Only in adjusted OR meta
  Wei et al[@b30-ndt-11-1121]            Zhejiang, People's Republic of China                 922                 Age ≥45 years; 55% M           SAS \>40                103/891 (11.6%)                                 10/163 (6.1%)                                       2.00 (1.02--3.92)   8                 Only in crude OR
  Cheung et al[@b31-ndt-11-1121]         Hong Kong, People's Republic of China                226                 Age 50.1±12.8 years; 50.2% M   HADS-A ≥8               31/113 (27.4%)                                  21/113 (18.6%)                                      1.71 (0.90--3.25)   7                 Only in crude OR
  Schmitz et al[@b32-ndt-11-1121]        German National Health, Germany                      4,149               Age 18--65 years; 52.3% M      DSM-IV                  148/1,656 (8.9%)                                224/2,500 (9.0%)                                    1.12 (0.89--1.39)   8                 Only in crude OR meta
  Hildrum et al[@b20-ndt-11-1121]        Nord-Trøndelag Health Study, Norway                  60,799              Age 20--89 years; 48.5% M      HADS-A ≥8                                                                                                                   0.90 (0.82--0.99)   7                 Only in adjusted OR
  Han et al[@b33-ndt-11-1121]            Nanjing, People's Republic of China                  740                 Age ≥35 years; 34.7% M         SAS \>40                31/326 (9.5%)                                   18/414 (4.3%)                                       2.45 (1.23--4.89)   7                 
  Grimsrud et al[@b15-ndt-11-1121]       South African Stress and Health, South African       4,351               Age ≥18 years; 46.3% M         DSM-IV                  105/767 (13.7%)                                 270/3,584 (7.5%)                                    1.55 (1.10--2.18)   9                 
  Carroll et al[@b34-ndt-11-1121]        Vietnam Experience Study, USA                        4,180               Age 31--49 years; 100% M       DSM-III                 171/1,381 (12.4%)                               232/2,801 (8.3%)                                    1.48 (1.18--1.87)   8                 
  Hildingh and Baigi[@b35-ndt-11-1121]   National Institute of Public Health, Sweden          12,166              Age 18--84 years; 45.4% M      Dichotomous variables                                                                                                       1.45 (1.28--1.64)   8                 Only in adjusted OR meta
  Saboya et al[@b36-ndt-11-1121]         Hospital São Lucas, Brazil                           302                 Age ≥18 years; 20.2% M         STAI ≥40                84/152 (55.3%)                                  67/150 (44.7)                                       2.83 (1.55--5.18)   7                 
  Fiedorowicz et al[@b37-ndt-11-1121]    National Comorbidity Survey- Replication, USA        5,692               Age ≥18 years; 41.8% M         DSM-IV                                                                                                                      1.48 (1.22--1.80)   9                 Only in adjusted OR meta
  Wiltink et al[@b18-ndt-11-1121]        Gutenberg Heart Study, Germany                       5,000               Age 35--74 years; 50.8% M      Mini-Spin; GAD; PHQ     354/2,058 (17.2%)                               403/1,938 (20.8)                                    1.08 (0.91--1.29)   8                 Only in adjusted OR meta
  Stein et al[@b11-ndt-11-1121]          World Mental Health Surveys, World                   52,095              Age ≥18 years; M               DSM-IV                                                                                                                      1.16 (1.08--1.25)   7                 Only in adjusted OR meta

**Abbreviations:** M, male; STAI, Spielberger State-Trait Anxiety; SAS, Self-Rating Anxiety Scale; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; DSM, Diagnostic and Statistical Manual of Mental Disorders; GAD, Generalized Anxiety Disorder; PHQ, Patient Health Questionnaire; Mini-Spin, Mini-Social Phobia Inventory; HP, hypertension; OR, odds ratio; CI, confidence interval; meta, meta-analysis.

###### 

Characteristics of prospective studies included in the meta-analysis

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reference                             Study name, country                                             Incident case subjects/total sample size   Follow-up (years)   Sample composition                   Anxiety measures                  OR/RR/HR (95% CI)    Quality   Adjustment factors
  ------------------------------------- --------------------------------------------------------------- ------------------------------------------ ------------------- ------------------------------------ --------------------------------- -------------------- --------- ----------------------------------------------------------------------------------------------------------------------------------------
  Markovitz et al[@b38-ndt-11-1121]     Framingham Heart Study, USA                                     140/330                                    18--20              Age 45--59 years; 100% M             Tension scale ≥0.7                2.19 (1.22--3.94)    8         Age, initial systolic blood pressure, initial heart rate, relative weight, alcohol intake, glucose intolerance, smoking, and education

  Jonas et al[@b39-ndt-11-1121]         National Health and Nutrition Examination Survey, USA           493/2,992                                  7--16               Age 25--64 years; 43.3% M            GWB-A                             1.42 (1.21--1.66)    8         Age, systolic blood pressure, education, smoking, BMI, alcohol, initial heart rate, and other disease

  Raikkonen et al[@b40-ndt-11-1121]     Healthy Women Study, USA                                        75/541                                     9.2                 Age 42--50 years; 0% M               STAI, FTS, Social Anxiety Scale   1.18 (1.04--1.33)    7         Only in crude OR meta

  Shinn et al[@b17-ndt-11-1121]         Reno Diet Heart Study, USA                                      55/370                                     4                   Age 20--75 years; 27.2% M            GWB-A \<13                        0.70 (0.30--1.64)    8         Age, BMI, systolic blood pressure, sex, parental history of hypertension, anxiolytic use

  Yan et al[@b6-ndt-11-1121]            Coronary Artery Risk Development in Young Adult, USA            430/3,156                                  10                  Age 23--35 years; 44.4% M            STAI \<30                         1.32 (1.09--1.60)    9         Age, sex, BMI, systolic blood pressure, education, alcohol and other psychosocial factors

  Johannessen et al[@b12-ndt-11-1121]   Danish Psychiatric Register, Denmark                            966/75,268                                 25                  Age \>18 years; 26.5% M              ICD-8\                            1.96 (1.73--2.22)    7         Gender
                                                                                                                                                                                                            ICD-10                                                           

  Ginty et al[@b13-ndt-11-1121]         Dutch Famine Birth Cohort Study, The Netherlands                219/455                                    5.5                 Mean age 58.22±0.91 years; 50.8% M   HADS-A ≥8                         2.08 (1.17--3.72)    8         Age, sex, socioeconomic status, smoking, sports participation, alcohol consumption, SBP, antidepressant and anxiolytic medication

  Bacon et al[@b14-ndt-11-1121]         Mechanisms and Outcomes of Myocardial Silent Ischemia, Canada   16/190                                     1                   Age ≥18 years; 60.5% M               DSM-IV                            6.57 (1.82--23.76)   8         Age, sex, BMI, smoking status, and psychiatric medication
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** BMI, body mass index; M, male; GWB-A, General Well-Being Schedule-Anxiety; STAI, Spielberger State-Trait Anxiety; FTS, Framingham Tension Scale; ICD, International Classification of Diseases; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; DSM, Diagnostic and Statistical Manual of Mental Disorders; OR, odds ratio; RR, relative risk; HR, hazard ratio; CI, confidence interval; SBP, systolic blood pressure.

###### 

Subgroup analyses to explore source of heterogeneity

  Subgroups                           Cross-sectional studies   Prospective studies                                     
  ----------------------------------- ------------------------- --------------------- ---------------------- --- ------ ----------------------
  Location                                                                                                              
   American                           2                         0.0                   1.480 (1.276--1.717)   6   66.2   1.366 (1.124--1.660)
   European                           5                         91.4                  1.237 (0.956--1.601)   2   0.0    1.965 (1.740--2.220)
   East Asian                         3                         0.0                   2.014 (1.370--2.961)              
   Other                              3                         81.3                  1.571 (1.032--2.390)              
  Diagnosis of anxiety                                                                                                  
   Structured diagnostic interviews   5                         62.9                  1.308 (1.138--1.504)   2   70.4   3.010 (0.968--9.355)
   Self--report symptom scales        8                         89.3                  1.575 (1.195--2.075)   6   55.4   1.354 (1.153--1.590)
  Age                                                                                                                   
   Middle--aged                       8                         78.6                  1.611 (1.333--1.947)   5   83.5   1.543 (1.169--2.038)
   Other                              5                         80.3                  1.146 (0.933--1.408)   3   72.7   1.632 (1.017--2.620)
  Sex                                                                                                                   
   Male                               4                         25.7                  1.410 (1.208--1.645)   3   75.9   2.063 (1.395--3.052)
   Female                             3                         70.9                  1.533 (1.005--2.339)   3   88.0   1.421 (1.031--1.957)
  Follow--up, years                                                                                                     
   \<7                                                                                                       3   77.5   1.945 (0.677--5.590)
   ≥7                                                                                                        5   88.8   1.505 (1.192--1.900)

**Note:** *I*^2^ indicates heterogeneity.

**Abbreviations:** OR, odds ratio; HR, hazard ratio; CI, confidence interval.
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